港股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

高瓴概念

508.965

-21.195-4.00%

涨家数：5

跌家数：49

平家数：1

市盈率：- -

高：530.970

开：530.107

低：506.286

收：530.160

数据加载中...

京东健康去年盈利超41亿元，复旦复华终止收购美丽人生，复星医药1类新药报产，恒瑞医药1类新药获批临床

汇丰：欧洲央行渐进降息或提振风险资产

机构：欧洲央行可能已非常接近中性利率

和黄医药(00013.HK)HMPL-453治疗肝内胆管癌II期临床试验已完成患者入组

阿斯达克财经

百济神州授出合共3.26万股受限制股份单位

百济神州(06160)授出购股权及受限制股份单位

百济神州(06160.HK)授出合共3.26万股受限制股份单位

中红医疗：子公司获得医疗器械注册证

心通医疗-B预期2024年净亏损同比收窄约87%至94%

格隆汇资讯

机构：欧洲央行如期降息避免引发市场动荡，未来不确定性仍存

暴降70%！泰格医药闪崩，CRO失去最后避风港

心通医疗-B(02160)发盈警预期2024年净亏损约3000万-6000万元同比减少约87%至94%

智通财经网

京东健康2024年业绩超预期总收入达到582亿元

高瓴大幅减持百济神州：或套现50亿仍是重要股东

富达国际减持海吉亚医疗(06078)113.48万股每股作价约16.83港元

石药集团：I类新药双功能融合蛋白药物JMT108获临床试验批准

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/BK1583/news?page=12"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1583"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1583\",,,,,undefined,":{"symbol":"BK1583","market":"HK","secType":"PLATE","nameCN":"高瓴概念","latestPrice":508.9653,"timestamp":1741585200769,"preClose":530.16,"halted":0,"volume":435480842,"delay":0,"changeRate":-0.039978,"change":-21.194672,"pbRate":2.561308,"amount":11297246754,"amplitude":0.04656,"prevYearClose":446.93042,"fiveDayClose":491.838,"twentyDayClose":478.478,"turnoverRate":0.003165,"marketCap":2834992817664,"floatMarketCap":2252658073088,"peRate":34.961436},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1583\",,,,,undefined,":{"symbol":"BK1583","high":530.9704,"amplitude":0.04656,"preClose":530.16,"low":506.28616,"pbRate":"2.561308","latestPrice":508.9653,"volume":435480842,"delay":0,"open":530.1071,"prevYearClose":446.93042,"prevWeekClose":530.16,"prevMonthClose":492.906,"prevQuarterClose":446.93,"fiveDayClose":491.838,"twentyDayClose":478.478,"sixtyDayClose":472.845,"secType":"PLATE","market":"HK","turnoverRate":0.003165,"peRate":34.961436,"marketCap":2834992817664,"floatMarketCap":2252658073088,"timestamp":1741585200769,"nameCN":"高瓴概念"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1583\",,,,undefined,":{"bkCode":"BK1583","up":5,"down":49,"flat":1},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1583\",pageSize:16,pageCount:12,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2517199543","title":"京东健康去年盈利超41亿元，复旦复华终止收购美丽人生，复星医药1类新药报产，恒瑞医药1类新药获批临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2517199543","media":"谈医说药","labels":["productRelease","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517199543?lang=zh_cn&edition=fundamental","pubTime":"2025-03-06 23:38","pubTimestamp":1741275504,"startTime":"0","endTime":"0","summary":"截至公告披露日，申劲锋未持有公司股份。复旦复华：公司决定终止收购宁波美丽人生医药生物科技发展有限公司51%股权。终止原因是上国仲认为案涉《股权收购协议》已经成立但尚未生效。该原料药用于治疗高血压症，浙江新赛科于2023年8月15日提交上市申请，2025年3月5日获得批准。归属于上市公司股东的净利润1.93亿元，同比增长9.17%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307022303abebaf89&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307022303abebaf89&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,merge","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1571","BK1515","BK1589","06618","BK1247","86618","LU0456827905.SGD","LU0051755006.USD","BK1591","BK1191","600196","02196","BK1593","BK1142","BK1583"],"gpt_icon":0},{"id":"2517169950","title":"汇丰：欧洲央行渐进降息或提振风险资产","url":"https://stock-news.laohu8.com/highlight/detail?id=2517169950","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517169950?lang=zh_cn&edition=fundamental","pubTime":"2025-03-06 23:13","pubTimestamp":1741274034,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"0d6184e4d27e8e91b8b00e52597fd1b8","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["HSBC","LU0310800965.SGD","BK1229","BK4521","BK4585","BK4588","HK0000934320.USD","LU1267930227.SGD","LU0052756011.USD","LU2236285917.USD","BK4207","BK1542","09983","BK1583","BK1258","LU0128525689.USD"],"gpt_icon":0},{"id":"2517169988","title":"机构：欧洲央行可能已非常接近中性利率","url":"https://stock-news.laohu8.com/highlight/detail?id=2517169988","media":"金十财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517169988?lang=zh_cn&edition=fundamental","pubTime":"2025-03-06 23:10","pubTimestamp":1741273822,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://flash-api.jin10.com/get_flash_list?channel=2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_jinshicaijing","symbols":["ZTmain","09983","BK1542","TNmain","UBmain","BK1583","ZNmain","BK1258","ZBmain","BK1229","ZFmain"],"gpt_icon":0},{"id":"2517169457","title":"和黄医药(00013.HK)HMPL-453治疗肝内胆管癌II期临床试验已完成患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2517169457","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517169457?lang=zh_cn&edition=fundamental","pubTime":"2025-03-06 23:05","pubTimestamp":1741273500,"startTime":"0","endTime":"0","summary":"和黄医药(00013.HK) 公布，HMPL-453(fanregratinib)用于治疗伴有成纤维细胞生长因子受体2融合/重排的肝内胆管癌患者的II期临床试验已完成患者入组。预计2025年年底左右公布研究的顶线结果。该研究旨在评估HMPL-453用于治疗伴有FGFR2融合/重排的晚期肝内胆管癌患者的疗效、安全性和药代动力学。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-03-06 16:25。)AASTOCKS新闻","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20220520173825120_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20220520173825120_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1422784/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1576","BK1141","BK1587","03347","00013","BK1583","BK1588","BK1191"],"gpt_icon":0},{"id":"2517116937","title":"百济神州授出合共3.26万股受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2517116937","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517116937?lang=zh_cn&edition=fundamental","pubTime":"2025-03-06 22:37","pubTimestamp":1741271821,"startTime":"0","endTime":"0","summary":"格隆汇3月6日丨百济神州(06160.HK)公告，于2025年3月3日，董事会薪酬委员会根据2016期权及激励计划的条款向一名承授人授出可认购合共1,100股美国存托股份的购股权并向一百五十一名承授人授出涉及合共32,579股美国存托股份的受限制股份单位。【免责声明】本文仅代表作者本人观点，与和讯网无关。和讯网站对文中陈述、观点判断保持中立，不对所包含内容的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部责任。邮箱：news_center@staff.hexun.com","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306224232989eb6ef&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306224232989eb6ef&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","BK1161","BK1500","06160","LU2328871848.SGD","LU0588546209.SGD","LU1969619763.USD","LU0307460666.USD","BK1588"],"gpt_icon":0},{"id":"2517853165","title":"百济神州(06160)授出购股权及受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2517853165","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517853165?lang=zh_cn&edition=fundamental","pubTime":"2025-03-06 22:15","pubTimestamp":1741270511,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百济神州(06160)发布公告，于2025年3月3日，董事会薪酬委员会根据2016期权及激励计划的条款授予一名承授人可认购合共1100股美国存托股份的购股权。于2025年3月3日，董事会薪酬委员会根据2016期权及激励计划的条款授予151名承授人合共3.26万股美国存托股份受限制股份单位。该等受限制股份单位相当于42.35万股股份，约占本公告之日公司发行股份总数的0.03%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1258811.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1500","688235","06160","ONC","BK1588","BK1583","LU2328871848.SGD","BK1161","BK4139","LU0307460666.USD","LU1969619763.USD","LU0588546209.SGD","BK0239"],"gpt_icon":0},{"id":"2517163194","title":"百济神州(06160.HK)授出合共3.26万股受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2517163194","media":"格隆汇","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517163194?lang=zh_cn&edition=fundamental","pubTime":"2025-03-06 22:12","pubTimestamp":1741270358,"startTime":"0","endTime":"0","summary":"格隆汇3月6日丨百济神州(06160.HK)公告，于2025年3月3日，董事会薪酬委员会根据2016期权及激励计划的条款向一名承授人授出可认购合共1,100股美国存托股份的购股权并向一百五十一名承授人授出涉及合共32,579股美国存托股份的受限制股份单位。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/03/06221248575249.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1161","BK0239","LU0588546209.SGD","LU1969619763.USD","688235","BK1500","BK4139","06160","LU0307460666.USD","LU2328871848.SGD","BK1588","ONC","BK1583"],"gpt_icon":0},{"id":"2517165045","title":"中红医疗：子公司获得医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2517165045","media":"证券","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517165045?lang=zh_cn&edition=fundamental","pubTime":"2025-03-06 22:08","pubTimestamp":1741270080,"startTime":"0","endTime":"0","summary":"证券日报网讯 3月6日晚间，中红医疗发布公告称，公司子公司深圳迈德瑞纳生物科技有限公司（简称“迈德瑞纳”）于近期取得了广东省药品监督管理局颁发的《中华人民共和国医疗器械注册证》，迈德瑞纳申报的肠内营养泵医疗器械注册证已审批通过。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-03-06/doc-inenttpc3265800.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1100","BK1574","09997","BK1583","159883","BK1222","BK0220","09996","300981"],"gpt_icon":0},{"id":"2517168156","title":"心通医疗-B预期2024年净亏损同比收窄约87%至94%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517168156","media":"格隆汇资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517168156?lang=zh_cn&edition=fundamental","pubTime":"2025-03-06 21:58","pubTimestamp":1741269522,"startTime":"0","endTime":"0","summary":"格隆汇3月6日丨心通医疗-B公告，根据对集团截至2024年12月31日止年度未经审核管理账目的初步审阅及对董事会目前可得最新资料的评估，集团预期报告期录得净亏损约人民币3000万元至人民币6000万元，较截至2023年12月31日止年度减少约87%至94%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306215850989eaca2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306215850989eaca2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","BK1100","02160","BK1574"],"gpt_icon":0},{"id":"2517150447","title":"机构：欧洲央行如期降息避免引发市场动荡，未来不确定性仍存","url":"https://stock-news.laohu8.com/highlight/detail?id=2517150447","media":"金十财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517150447?lang=zh_cn&edition=fundamental","pubTime":"2025-03-06 21:58","pubTimestamp":1741269483,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"0d6184e4d27e8e91b8b00e52597fd1b8","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://flash-api.jin10.com/get_flash_list?channel=2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_jinshicaijing","symbols":["BK1542","BK1583","BK1229","09983","HK0000934320.USD","BK1258"],"gpt_icon":0},{"id":"2517168193","title":"暴降70%！泰格医药闪崩，CRO失去最后避风港","url":"https://stock-news.laohu8.com/highlight/detail?id=2517168193","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517168193?lang=zh_cn&edition=fundamental","pubTime":"2025-03-06 21:58","pubTimestamp":1741269480,"startTime":"0","endTime":"0","summary":"AI浪潮袭来，CRO行业正从“人力密集型”向“技术驱动型”演进。行业结构性调整的阵痛，无人能幸免。药明、康龙化成之后，轮到CRO血统最纯正的大哥——泰格医药了。作为中国CXO行业“最后的堡垒”，CRO一哥终于顶不住了——2024年迎来了业绩创纪录式的大跌：根据预告，其上市以来年营收首次出现下滑；归母净利润预计同比骤降72%-81%，这一力度也是上市后首次，盈利压力凸显。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306221121989eafa8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306221121989eafa8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03347","BK1141","BK1576","BK1583"],"gpt_icon":0},{"id":"2517150236","title":"心通医疗-B(02160)发盈警 预期2024年净亏损约3000万-6000万元 同比减少约87%至94%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517150236","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517150236?lang=zh_cn&edition=fundamental","pubTime":"2025-03-06 21:55","pubTimestamp":1741269335,"startTime":"0","endTime":"0","summary":"心通医疗-B(02160)公布，该集团预期2024年取得净亏损约人民币3000万-...","market":"us","thumbnail":"https://img.zhitongcaijing.com/gonggao/ztcj_announce_37.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/gonggao/ztcj_announce_37.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1258805.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1100","02160","BK1583","BK1574"],"gpt_icon":0},{"id":"2517150788","title":"京东健康2024年业绩超预期 总收入达到582亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517150788","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517150788?lang=zh_cn&edition=fundamental","pubTime":"2025-03-06 21:34","pubTimestamp":1741268092,"startTime":"0","endTime":"0","summary":"本报讯（记者袁传玺）3月6日，京东健康股份有限公司（以下简称“京东健康”）发布2024年全年业绩公告。2024年，京东健康总收入为582亿元，非国际财务报告准则指标下（Non-IFRS）净利润达47.9亿元，收入和净利润超过市场预期。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202503063338762475.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0456827905.SGD","BK1571","BK1591","BK1515","BK1142","LU0051755006.USD","BK1247","BK1583","86618","BK1589","06618"],"gpt_icon":0},{"id":"2517157675","title":"高瓴大幅减持百济神州：或套现50亿 仍是重要股东","url":"https://stock-news.laohu8.com/highlight/detail?id=2517157675","media":"雷递网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517157675?lang=zh_cn&edition=fundamental","pubTime":"2025-03-06 21:29","pubTimestamp":1741267769,"startTime":"0","endTime":"0","summary":"由于百济神州这两日股价处于低点，若以今日股价计算，高瓴套现50亿港元。这是2024年12月以来，高瓴再次减持百济神州。百济神州此前公告称，高瓴于2023年6月8日至 2024年12月2日通过集中竞价和大宗交易方式合计减持21,997,317股。百济神州年营收272亿近期，百济神州发布业绩快报。不过，过去半年的时间，百济神州股价持续上涨，高瓴则持续减持，共套现至少超过70亿港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306212955963c3dd5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306212955963c3dd5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2328871848.SGD","BK1161","BK1500","LU1969619763.USD","06160","LU0307460666.USD","BK1583","BK1588","688235","LU0588546209.SGD"],"gpt_icon":0},{"id":"2517531159","title":"富达国际减持海吉亚医疗(06078)113.48万股 每股作价约16.83港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517531159","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517531159?lang=zh_cn&edition=fundamental","pubTime":"2025-03-06 20:19","pubTimestamp":1741263559,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，2月27日，富达国际减持海吉亚医疗(06078)113.48万股，每股作价16.8258港元，总金额约为1909.39万港元。减持后最新持股数目为3674.96万股，最新持股比例为5.91%。本交易涉及其他关联方：Pandanus Associates Inc.和Pandanus Partners L.P.。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1258747.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0502904849.HKD","LU0329678170.USD","BK4548","LU0455707207.USD","LU0329678337.USD","BK4503","BK4232","LU0737861772.HKD","BK1583","BK4022","LU0327786744.USD","LU2242644610.SGD","BK1209","LU0456842615.SGD","BK4539","LU0572944931.SGD","BK4526","06078","LU2488822045.USD","YMM"],"gpt_icon":0},{"id":"2517445159","title":"石药集团：I类新药双功能融合蛋白药物JMT108获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2517445159","media":"财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517445159?lang=zh_cn&edition=fundamental","pubTime":"2025-03-06 19:58","pubTimestamp":1741262311,"startTime":"0","endTime":"0","summary":"近日，石药集团发布JMT108获中国临床试验批准的公告。该产品是一种重组全人源抗PD-1且融合IL-15的双功能融合蛋白，通过靶向PD-1阳性肿瘤浸润免疫细胞，解除PD-1和PD-L1相互作用导致的免疫抑制，并通过PD-1抗体结合依赖性地激活IL-15下游信号通路，进一步促进相关免疫细胞的增殖和活化，从而达到增强的抗肿瘤疗效。本次获批的临床适应症为晚期恶性肿瘤。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306200013abeb4e69&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306200013abeb4e69&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1226287792.SGD","BK1521","IE0008368742.USD","IE00BZ08YR35.GBP","LU1152091754.HKD","IE00B031HY20.USD","LU1226288170.HKD","IE0008369823.USD","LU1152091168.USD","IE00BZ08YS42.EUR","LU1226287529.USD","03347","01093","LU1008478684.HKD","LU1960683339.HKD","LU0326950275.SGD","LU1807302812.USD","IE00B543WZ88.USD","IE00BZ08YT58.USD","BK1191","BK1515","LU0072913022.USD","BK1583","LU1226288253.USD","SG9999004220.SGD","IE00B5MMRT66.SGD","LU1226287875.USD","BK1141","LU0067412154.USD","LU0501845795.SGD","LU1951186391.HKD","BK1576","LU1993786604.SGD","LU0140636845.USD","LU0880133367.SGD"],"gpt_icon":0}],"pageSize":16,"totalPage":63,"pageCount":12,"totalSize":1003}]}}